粗大运动功能测量在大多数研究中用于测量脑瘫儿童的粗大运动功能。在许多研究中,包括那些评估高压治疗效果的人,由于缺乏对照组,粗大运动功能测量值的变化可能被误解.粗大运动功能测量演变比(GMFMER)使用来自粗大运动功能分类系统曲线的历史数据,并允许通过考虑粗大运动功能测量的自然预期演变来重新分析使用粗大运动功能测量的先前发表的研究。由于GMFMER由记录的粗大运动功能测量分数增加与研究期间自然进化的预期增加之间的比率定义(自然进化产生的GMFMER为1),评估和比较不同治疗方法的疗效变得容易。
■这项研究的目的是重新审视使用不同剂量的高压治疗进行的研究,并将这些研究中测量的GMFMER与评估各种推荐治疗对脑瘫儿童的影响的研究进行比较。
■进行PubMed搜索以纳入使用粗大运动功能测量来评估物理治疗效果的研究,选择性背根切断术,肉毒杆菌毒素注射,海马疗法,干细胞,或者高压治疗.计算每组纳入研究的GMFMER。
■纳入了44项研究,统计4项研究评估不同剂量的高压氧治疗对脑瘫患儿的影响。由于一些研究有几个武器,GMFMER已计算为69组。接受不到2小时/周物理治疗的组的平均GMFMER为2.5±1.8,而在非常密集的物理治疗的情况下,它增加到10.3±6.1。干细胞的GMFMER,选择性背根切断术,海马疗法,肉毒杆菌毒素治疗是,分别为6.0±5.9、6.5±2.0、13.3±0.6和5.0±2.9。接受高压治疗的儿童组的GMFMER高压氧治疗为28.1±13.0,高压空气为29.8±6.8。
■对GMFMER的纳入研究的分析表明,与其他公认的治疗方法相比,高压治疗可导致脑瘫儿童粗大运动功能的进展。
The Gross Motor Function Measure is used in most studies measuring gross motor function in children with cerebral palsy. In many studies, including those evaluating the effect of hyperbaric treatment, the Gross Motor Function Measure variations were potentially misinterpreted because of the lack of control groups. The Gross Motor Function Measure Evolution Ratio (GMFMER) uses historical data from the Gross Motor Function Classification System curves and allows to re-analyze previous published studies which used the Gross Motor Function Measure by considering the natural expected evolution of the Gross Motor Function Measure. As the GMFMER is defined by the ratio between the recorded Gross Motor Function Measure score increase and the expected increase attributed to natural evolution during the duration of the study (natural evolution yields a GMFMER of 1), it becomes easy to assess and compare the efficacy of different treatments.
UNASSIGNED: The objective of this study is to revisit studies done with different dosage of hyperbaric treatment and to compare the GMFMER measured in these studies with those assessing the effects of various recommended treatments in children with cerebral palsy.
UNASSIGNED: PubMed Searches were conducted to included studies that used the Gross Motor Function Measure to evaluate the effect of physical therapy, selective dorsal rhizotomy, botulinum toxin injection,
hippotherapy, stem cell, or hyperbaric treatment. The GMFMER were computed for each group of the included studies.
UNASSIGNED: Forty-four studies were included, counting 4 studies evaluating the effects of various dosage of hyperbaric treatment in children with cerebral palsy. Since some studies had several arms, the GMFMER has been computed for 69 groups. The average GMFMER for the groups receiving less than 2 h/week of physical therapy was 2.5 ± 1.8 whereas in context of very intensive physical therapy it increased to 10.3 ± 6.1. The GMFMER of stem cell, selective dorsal rhizotomy,
hippotherapy, and botulinum toxin treatment was, 6.0 ± 5.9, 6.5 ± 2.0, 13.3 ± 0.6, and 5.0 ± 2.9, respectively. The GMFMER of the groups of children receiving hyperbaric treatment were 28.1 ± 13.0 for hyperbaric oxygen therapy and 29.8 ± 6.8 for hyperbaric air.
UNASSIGNED: The analysis of the included studies with the GMFMER showed that hyperbaric treatment can result in progress of gross motor function more than other recognized treatments in children with cerebral palsy.